Mangalam Drugs and Organics Ltd banner

Mangalam Drugs and Organics Ltd
NSE:MANGALAM

Watchlist Manager
Mangalam Drugs and Organics Ltd Logo
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
Watchlist
Price: 31.66 INR -1.4% Market Closed
Market Cap: ₹501.2m

Net Margin

-13%
Current
Declining
by 10.4%
vs 3-y average of -2.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-13%
=
Net Income
₹-309.2m
/
Revenue
₹2.4B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-13%
=
Net Income
₹-309.2m
/
Revenue
₹2.4B

Peer Comparison

Country Company Market Cap Net
Margin
IN
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
501.1m INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
959.3B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
585.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
291.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
238.2B GBP
Loading...
CH
Novartis AG
SIX:NOVN
242.2B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
305.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
151.4B USD
Loading...
UK
GSK plc
XETRA:GS71
103.6B EUR
Loading...

Market Distribution

Lower than 90% of companies in India
Percentile
10th
Based on 5 531 companies
10th percentile
-13%
Low
-305 007.7% — 2.1%
Typical Range
2.1% — 11.6%
High
11.6% — 1 221 633.3%
Distribution Statistics
India
Min -305 007.7%
30th Percentile 2.1%
Median 5.8%
70th Percentile 11.6%
Max 1 221 633.3%

Mangalam Drugs and Organics Ltd
Glance View

Market Cap
501.2m INR
Industry
Pharmaceuticals

Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-05-26. The firm handles marketing in both domestic and export markets. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm offers its products to Italy, Russia, China, Turkey, Nigeria, Uganda, Kenya and Pakistan. The company has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.

MANGALAM Intrinsic Value
113.9 INR
Undervaluation 72%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-13%
=
Net Income
₹-309.2m
/
Revenue
₹2.4B
What is Mangalam Drugs and Organics Ltd's current Net Margin?

The current Net Margin for Mangalam Drugs and Organics Ltd is -13%, which is below its 3-year median of -2.5%.

How has Net Margin changed over time?

Over the last 3 years, Mangalam Drugs and Organics Ltd’s Net Margin has decreased from 2.9% to -13%. During this period, it reached a low of -13% on Jan 1, 2026 and a high of 2.9% on Dec 31, 2022.

Back to Top